Rights and permissions
About this article
Cite this article
NZ Pharmac saves, but says no to imatinib mesylate. Pharmacoecon. Outcomes News 374, 12 (2002). https://doi.org/10.1007/BF03279440
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03279440